FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:283-284 July 26, 2001 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article by Kreitman, R. J. PubMed Citation

The search for effective and specific antineoplastic therapy has led to considerable interest in antitumor antibodies. Attempts to treat cancer with antibodies date back to the early 1900s, but progress was stalled until discovery in 1975 of a way to produce mouse monoclonal antibodies in vitro.¹ Early trials with these antibodies in patients with cancer found only short-lived responses.² One exception is a class of mouse monoclonal antibodies against the unique antigen-binding structure (idiotype) of the surface immunoglobulin on a neoplastic B cell, which can be effective in low-grade non-Hodgkin's lymphoma.³

These early attempts drew attention to the potential benefits . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pan, X. Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., Lee, R. J. (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta -targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100: 594-602 [Abstract] [Full Text]